Pharmacotherapy for obesity

Research output: Contribution to journalArticle

Standard

Pharmacotherapy for obesity. / Li, M; Cheung, Bernard.

In: British Journal of Clinical Pharmacology, Vol. 68, No. 6, 01.12.2009, p. 804-810.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Bibtex

@article{60a1c145875b4565b1502afda71bf0f2,
title = "Pharmacotherapy for obesity",
abstract = "Obesity is associated with increased risk of conditions such as hypertension, dyslipidaemia, diabetes mellitus, and obstructive sleep apnoea. Pharmacotherapy for obesity should be considered in combination with lifestyle changes in obese patients, or overweight patients with other conditions that put them at risk of developing heart disease. Sibutramine and orlistat are the only two anti-obesity medications approved for long-term use. Sibutramine is a serotonergic and adrenergic drug that reduces food intake. Orlistat is a gastrointestinal lipase inhibitor that interferes with fat absorption. However, it commonly causes flatulence and diarrhoea. Rimonabant is the first of a series of endocannabinoid receptor antagonists. It was approved by the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMEA) as an adjunct to diet and exercise in treating obesity in 2006. However, despite the extensive clinical trial data, EMEA announced in 2008 that it has recommended suspension of rimonabant because of its psychiatric side effects. Studies evaluating the long-term safety and efficacy of anti-obesity agents are needed.",
keywords = "sibutramine, rimonabant, orlistat, anti-obesity drugs",
author = "M Li and Bernard Cheung",
year = "2009",
month = dec,
day = "1",
doi = "10.1111/j.1365-2125.2009.03453.x",
language = "English",
volume = "68",
pages = "804--810",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley",
number = "6",

}

RIS

TY - JOUR

T1 - Pharmacotherapy for obesity

AU - Li, M

AU - Cheung, Bernard

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Obesity is associated with increased risk of conditions such as hypertension, dyslipidaemia, diabetes mellitus, and obstructive sleep apnoea. Pharmacotherapy for obesity should be considered in combination with lifestyle changes in obese patients, or overweight patients with other conditions that put them at risk of developing heart disease. Sibutramine and orlistat are the only two anti-obesity medications approved for long-term use. Sibutramine is a serotonergic and adrenergic drug that reduces food intake. Orlistat is a gastrointestinal lipase inhibitor that interferes with fat absorption. However, it commonly causes flatulence and diarrhoea. Rimonabant is the first of a series of endocannabinoid receptor antagonists. It was approved by the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMEA) as an adjunct to diet and exercise in treating obesity in 2006. However, despite the extensive clinical trial data, EMEA announced in 2008 that it has recommended suspension of rimonabant because of its psychiatric side effects. Studies evaluating the long-term safety and efficacy of anti-obesity agents are needed.

AB - Obesity is associated with increased risk of conditions such as hypertension, dyslipidaemia, diabetes mellitus, and obstructive sleep apnoea. Pharmacotherapy for obesity should be considered in combination with lifestyle changes in obese patients, or overweight patients with other conditions that put them at risk of developing heart disease. Sibutramine and orlistat are the only two anti-obesity medications approved for long-term use. Sibutramine is a serotonergic and adrenergic drug that reduces food intake. Orlistat is a gastrointestinal lipase inhibitor that interferes with fat absorption. However, it commonly causes flatulence and diarrhoea. Rimonabant is the first of a series of endocannabinoid receptor antagonists. It was approved by the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMEA) as an adjunct to diet and exercise in treating obesity in 2006. However, despite the extensive clinical trial data, EMEA announced in 2008 that it has recommended suspension of rimonabant because of its psychiatric side effects. Studies evaluating the long-term safety and efficacy of anti-obesity agents are needed.

KW - sibutramine

KW - rimonabant

KW - orlistat

KW - anti-obesity drugs

U2 - 10.1111/j.1365-2125.2009.03453.x

DO - 10.1111/j.1365-2125.2009.03453.x

M3 - Article

C2 - 20002075

VL - 68

SP - 804

EP - 810

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

IS - 6

ER -